Press Releases

LONDON --(BUSINESS WIRE)--Aug. 19, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global Healthcare Conference in New York .

LONDON --(BUSINESS WIRE)--Jul. 31, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.

LONDON --(BUSINESS WIRE)--Jun. 18, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).

Primary endpoint did not achieve statistical significance in unipolar patient cohort Statistically significant and clinically meaningful benefits seen in select secondary endpoints; no safety concerns identified LONDON --(BUSINESS WIRE)--Jun. 6, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading

LONDON --(BUSINESS WIRE)--May 23, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida .

LONDON --(BUSINESS WIRE)--May 1, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.

LONDON --(BUSINESS WIRE)--Apr. 30, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel , Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024 . In this newly created position, Tezel will leverage his career

LONDON --(BUSINESS WIRE)--Apr. 25, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc. , is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the

LONDON --(BUSINESS WIRE)--Mar. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).

LONDON --(BUSINESS WIRE)--Mar. 20, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude

LONDON --(BUSINESS WIRE)--Mar. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to persons

LONDON --(BUSINESS WIRE)--Mar. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably

LONDON --(BUSINESS WIRE)--Mar. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida .

LONDON --(BUSINESS WIRE)--Feb. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights 1 Fourth-quarter revenue of $310.1 million

William Kozy will remain Board Chair LONDON --(BUSINESS WIRE)--Feb. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of

Move Reinforces Focus on Core Cardiopulmonary and Neuromodulation Businesses ACS Standalone Cannulae Products and Accessories to Transition Into Cardiopulmonary Business Unit LONDON --(BUSINESS WIRE)--Jan. 8, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today

LONDON --(BUSINESS WIRE)--Jan. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).